For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 0 | - | ||
| Research and development | 15,891 | 17,729 | ||
| General and administrative | 9,122 | 8,786 | ||
| Depreciation and amortization | 90 | 126 | ||
| Total operating expenses | 25,103 | 26,641 | ||
| Loss from operations | -25,103 | -26,641 | ||
| Gain from change in fair value of warrant liabilities | -24,441 | -6,125 | ||
| Loss on issuance of warrant liabilities | -30,962 | -847 | ||
| Transaction costs allocated to warrant liabilities | 1,407 | 993 | ||
| Loss on extinguishment of warrant liabilities | -614 | - | ||
| Other (expense) income, net | -20 | 43 | ||
| Interest income, net | 105 | 550 | ||
| Net loss | -33,560 | -21,763 | ||
| Foreign currency translation | - | -32 | ||
| Warrant deemed dividend | 104 | - | ||
| Comprehensive loss | - | -21,795 | ||
| Net loss available to common stockholders | -33,664 | - | ||
| Basic EPS | -28.42 | -6.32 | ||
| Basic Average Shares | 1,184,569 | 3,442,997 | ||
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)